Literature DB >> 26816816

How to evaluate sexual health in cancer patients: development of the EORTC sexual health questionnaire for cancer patients.

Eva Nagele1, Brenda Den Oudsten1, Elfriede Greimel1.   

Abstract

BACKGROUND: The aim of the study is to describe the development of a comprehensive European Organisation for Research and Treatment of Cancer (EORTC) questionnaire to assess sexual health of female and male cancer patients and for cancer survivors.
METHODS: According to the EORTC guidelines, the development of an EORTC sexual health questionnaire is typically organised in four phases. The first phases comprise a literature search following interviews with patient and health care professionals (HCPs) (phase 1) and the operationalization into items (phase 2). The translation process is formally conducted according to the EORTC QLG Translation guidelines with a rigorous forward-backward procedure supported by native speakers.
RESULTS: Studies on sexuality in oncology patients which were identified by a literature search predominantly focused on issues of activity, experiences of sexual dysfunction, and satisfaction with sexual functioning. The literature review identified themes beyond these aspects. In total 53 potentially relevant issues were presented to 107 patients and 83 HCPs, different evaluations were found.
CONCLUSIONS: A questionnaire that includes physical, psychological, and social aspects of sexuality of cancer survivors will be needed. Pre-testing and validation of the questionnaire will be done in future (phases 3 and 4). Divergent ratings of patients and professionals should be further investigated.

Entities:  

Keywords:  Cancer; European Organisation for Research and Treatment of Cancer (EORTC) sexual health questionnaire; sexual health

Year:  2015        PMID: 26816816      PMCID: PMC4708120          DOI: 10.3978/j.issn.2223-4683.2014.11.08

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


Introduction

An individual’s sexual response can be affected in a number of ways that involves the physical, psychological, interpersonal, and behavioural aspects of a person. The most common sexual problems for people who have cancer are loss of desire for sexual activity in both men and women, problems achieving and maintaining an erection in men, and pain with intercourse in women (1). Unlike many other physiological side effects of cancer treatment, sexual problems do not tend to resolve within the first year or two of disease-free survival (2-5) rather, they may remain constant and fairly severe or even continue to increase. Long-term effects of different treatment on sexual functioning have been studied in cervical cancer survivors (6,7). Existing research has mainly focused on women who have breast or gynecologic cancer and men who have prostate cancer (8). Less is known about how other types of cancers affect sexual health. Although it is unclear how much sexual problems influence a survivor’s rating of overall health-related quality of life, these problems are clearly bothersome to many patients and interfere with a return to normal post-treatment life. In 2014, the National Cancer Institute at the National Institutes of Health published data on some form of sexual dysfunction occurring in 40-100% of persons diagnosed with cancer (1,9-13). Sexual dysfunction is less broadly defined than sexuality and is characterized by dysfunction of one of the four phases of the sexual response cycle, or pain during intercourse (14,15). The World Health Organization (WHO) defines sexuality as a central aspect of being human throughout life and encompasses sex, gender identities and roles, sexual orientation, eroticism, pleasure, intimacy and reproduction. Comparatively, sexual health is defined as a state of physical, emotional, mental and social well-being relating to sexuality, and is not merely the absence of disease, dysfunction or infirmity (16). Cancer and cancer therapies are frequently associated with changes in sexual health. However, there is a lack of consensus regarding valid outcome measures for assessing sexual functioning in cancer patients (12,17). There is no single self-report measure that can be recommended for cancer clinical trials (18,19) on the basis of a broader definition of sexual health. Several modules for various cancer sites (e.g., breast, gynecologic, prostate) were developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC-QLG) which include a limited number of sexual functioning items. The U.S. National Institutes of Health PROMIS® Network has already developed a self-report measure of sexual function and satisfaction for cancer populations (20). However, the existing questionnaires do not cover the whole range of sexual health. Currently, there is no comprehensive instrument that assesses aspects of sexual health in a broader sense. The aim of the study is to develop a comprehensive EORTC questionnaire to assess sexual health of male and female cancer patients and for cancer survivors. We describe the development of the sexual health questionnaire according to the EORTC guidelines (21).

Materials and methods

According to the EORTC guidelines (21) the development of an EORTC questionnaire is typically organised in four phases. The first phases comprise a literature search following interviews with patients and health care professionals (HCPs) (phase 1) and the operationalization into items (phase 2).

Literature search and interviews

The literature search is focused on sexual health in cancer patients with a search strategy which was kept broad. The following combinations of keywords were used to identify papers in PubMed covering the period January 1993 to January 2012: ‘neoplasms[mesh]’ or ‘neoplas*[tw]’ or ‘tumor[tw]’ or ‘tumors[tw]’ or ‘tumou*[tw]’ or ‘cancer*[tw]’ or ‘carcinom*[tw]’ or ‘oncolog*[tw]’ and ‘sexuality[mesh]’ or ‘sexual function or sexual function[all fields]’ or ‘sexual function[tiab]’ or ‘sexual dysfunction’ or ‘sexual dysfunction [all fields]’ or ‘sexual dysfunction[tiab]’. Articles focusing on sexuality that conceptually exceeds issues relating to sexual function, sexual activity or sexual response cycle in cancer patients and/or cancer survivors were selected through title and abstract screening. For inclusion, original research articles had to be full reports in English and published in peer-reviewed journals. Qualitative and quantitative studies are included in the review. Additionally, an evaluation of measures related to sexuality in cancer patients was conducted (Den Oudsten et al., unpublished data). Issues which resulted from the literature search were summarized in an issue list. The same list was then presented to patients and HCPs recruited by collaborators within the EORTC Quality of Life Group for feedback on appropriateness of content and breadth of coverage on a four-point Likert scale. The following demographic data from the HCPs were asked: professional background, cancer sites they were most familiar with, duration of being involved in the care of patients with cancer, sex and country. A case report form including the most important clinical data related to disease and therapy was given to patients. The list of issues was translated into several languages. Members and collaborators of the EORTC-QLG spread out the questionnaire to other HCP specialists in oncology such as psycho-oncologists, radiotherapist or gynaecologists in more than 20 institutions in different countries ().
Table 1

Issue list

Sexual activity
   Frequency of sexual activity
   Reasons for being sexually inactive
   Satisfaction with the frequency of sexual activity
   Importance of having an active sexual life
   Level of hesitation to initiate sexual activities
Sexual desire
   Frequency of sexual desire
   Level of desire
   Distress caused by decreased libido
   Satisfaction with frequency of sexual desire
   Satisfaction with level of desire
Sexual arousal
   Frequency of sexual arousal
   Level of sexual arousal
   Satisfaction with level of sexual arousal
Orgasm
   Ability to achieve an orgasm
   Difficulty to reach an orgasm
   Satisfaction with the ability to orgasm
   Satisfaction with the frequency of orgasm
Side-effects influencing sexual activity
   Incontinence (urine/fecal) during foreplay or intercourse
   Hair loss (indirectly) affecting sexual response
   Fatigue/lack of energy affecting sex life
   Scarring/organ loss (indirectly) affecting sexual response/satisfaction
Pain
   Frequency of pain during/after sexual activity
   Level of pain during/after sexual activity
Intimacy
   Change in amount of affection expressed
   The level of emotional intimacy
   Satisfaction with level of affection or intimacy
Fear
   Fear that sex will be painful
   Fear of injury during intercourse
   Fear harming the incision during intercourse
Communication/Relationship issues
   Satisfaction communication partner
   Partner is afraid to touch, afraid to cause pain
   Experience of emotional distance from spouse
   Insecurity regarding ability to satisfy the partner
   Partner response to changes in sexual functioning: accepting/rejecting
Distress/bothered/satisfaction (general)
   Level of comfort with one’s sexuality
   Change in presence sexual fantasies
   Level of sexual enjoyment
   Sexual satisfaction
   Reduced sexual enjoyment
   To what extent are sexual dysfunctions distressing
Health care/aids
   Need for care because of sexual difficulties
   Communication about sexual issues with health professionals
Male sexual health
   Ejaculation
      Dry orgasm
      Retrograde ejaculation
   Erectile function
      Ability to get an erection
      Ability to maintain an erection (firm enough for sex)
      Satisfaction with ability to maintain erection or level of firmness
      Level of confidence in getting an erection and keeping one
   Masculinity
      Change in masculinity/feeling less masculine
Female sexual health
   Lubrication
      Insufficient/decreased lubrication
      Frequency of spotting/bleeding after sexual intercourse
   Femininity
      Change in femininity/feeling less feminine
      Masturbation (included after discussion during an EORTC QLG meeting)
For the final decision which issues on sexual health are definitely important for cancer patients, mean scores for relevance and priority ratings were defined according to the EORTC-QLG guidelines (21) using the following criteria: (I) mean score for HCPs <2 versus ≥2; and (II) mean score for patients <2 versus ≥2; (III) priority should have been rated by more than 30% of the HCPs; and (IV) >30% of patients as highly relevant to be included. Issues that met three or four of these criteria were kept in the list. Issues that met less than three criteria were deleted, unless the interviews provided strong arguments for retaining them. Additional new issues were included if they were mentioned by a considerable number of patients or HCPs. Based on the remaining issues the items for the provisional questionnaire were developed.

Operationalization into items

The process of translation is formally conducted according to the EORTC QLG Translation guidelines with a rigorous forward-backward procedure (18) supported by native speakers. The underlying English issues will be operationalised into items first. If items already have been used in another validated EORTC questionnaire they normally are included in their original wording. Questions are phrased in a way that they fit into the 4-point answering format of the EORTC ranging from “not at all” to “very much”. A time frame of 4 weeks is chosen as suggested in the EORTC guidelines (21). A standardized introduction was modified for the issue of sexual health. Phase 3 is the pilot-testing of the final item list and is actually under construction. A validation of the questionnaire will be done in phase 4.

Results

Results of the literature search

Many generic and cancer-specific sexual health issues have been identified in the literature review. A total of 4,518 articles were screened of which 3,461 articles were excluded because they did not focus on cancer patients and/or did not report sexuality as an outcome measure. Another 924 articles were excluded because they were literature reviews or presented only domain scores or were on sexual activity and sexual response cycle only. Finally, 65 articles were included in the systematic review. Apart from the frequency of sexual activity, sexual dysfunction and overall levels of satisfaction with sexual functioning, a number of issues were identified: sex-related guilt, anxiety, embarrassment, future prospects, quality of the relationship with the partner, changed feelings of sexual attractiveness, partner’s response to the changed situation, and the effectiveness and side effects of (medical) sex aids. These topics were used as underlying issues for the provisional sexual health questionnaire. Issues concerning sexual attractiveness were restricted to quantitative studies only. Many questionnaires for measuring different aspects of sexual health were found in the reviewed literature, but cancer-specific instruments were underrepresented. Sexual functioning was often assessed as part of (health-related) quality of life. Frequencies and sexual satisfaction were commonly assessed with a single item only. Qualitative designs to assess sexual functioning were used in 20 studies. The detailed results of the literature review are described elsewhere (Den Oudsten et al., unpublished data). Issues identified by the literature search were first checked for clinical relevance. A shortened list of 53 issues was then reviewed by a great number of patients (n=107) and HCPs (n=83).

Characteristics of patients and HCPs

Most of the patients had breast cancer (n=43; 40%), followed by colorectal (n=17; 16%), and head and neck cancer (n=14; 13%). All over the group cancer sites were well-balanced. The majority of patients were treated with surgery followed by radiation therapy and chemotherapy, and were under active treatment when they were interviewed. Half of the patients had no evidence of disease (n=53; 50%); a smaller number was newly diagnosed (n=17; 16%) or had a recurrent disease (n=11; 10%). A progression was stated for 10 patients. About a half had completed their treatment within the last 5 years, 8% more than 5 years ago and the others have not completed yet or did not provide any information on that. There were more female than male patients interviewed with a mean of 55 years (±11). The majority was living with a partner or family and had a sexual partner and was well-educated (,).
Table 2

Sociodemographic patient characteristics (N=107)

CharacteristicsN%
Gender
  Female6662
  Male4138
Age (years)
  20-3533
  36-503129
  51-655450
  66-851716
  Missing22
Living situation
  Living with partner or family9084
  Living alone1413
  Living with others22
  Missing11
Sexual partner
  Yes9084
  No1514
  Missing22
Education level
  Post compulsory school education4744
  University level3028
  Compulsory school education or less2422
  Missing66
Table 3

Clinical patient characteristics (N=107)

CharacteristicsN%
Treatment status
  Active treatment7267
  No active treatment3432
  Missing11
Treatment
  Surgery7671
  Radiation therapy6662
  Chemotherapy6258
  Anti-hormonal therapy2826
  Others55
Status of disease
  No evidence of disease5350
  Newly diagnosed1716
  Recurrence1110
  Progression109
  Missing1615
Years since diagnosis
  Less than 5 years ago8075
  5 to 10 years ago2019
  More than 10 years ago33
  Missing44
Time of completion
  During the last 5 years4542
  More than 5 years ago98
  Not completed yet44
  Missing4946
Menopausal status (N=66)
  Post-menopausal3045
  Pre-menopausal1929
  Treatment-related menopause1320
  Missing46
Various experts from different disciplines, mainly employed as medical doctors (n=53; 64%), psycho-oncologists (n=16; 21%) or nurses (n=3), reviewed the issue list. Gender was equally distributed and their clinical experiences mostly ranged from 10 to 20 years. Most of the HCPs were familiar with gynecologic cancer (n=29; 26%), followed by colorectal/gastrointestinal (n=21; 19%), breast (n=18; 16%), prostate/testicular (n=9; 8%) and other cancer sites (e.g., head and neck or lung cancer) (n=33; 31%).

Interview results

Most of the issues on satisfaction as well as the importance of having an active sexual life were rated as highly important in the sexual health questionnaire by both patients and HCPs. There were several issues referring to satisfaction (e.g., satisfaction with the level of affection or intimacy, satisfaction with the frequency of sexual activity, satisfaction with the communication with the partner and sexual satisfaction). No specific issues for female patients were rated as highly important. Male patients additionally rated their level of confidence in getting an erection and keeping one as very important. These issues met all four criteria on relevance and priority. Issues on sexual arousal, orgasm-related issues and general issues on sexual enjoyment were also rather important for female and male patients and HCPs. A very low relevance and priority had the issues on hair loss, masturbation and sexual desire (frequency, level). Also issues about fear harming the incision during intercourse, retrograde ejaculation and changes in sexual fantasies did not fulfill the criteria to be further included. When considering the mean relevance only, all presented issues except five were more often rated as highly relevant for cancer patients by HCPs than by patients. There seems to be a similar relevance for sexual desire (frequency, level), satisfaction (with level of affection or intimacy and with the communication with the partner) and the level of emotional intimacy. All other issues were rated more relevant to be included in the questionnaire for HCPs, not for patients. The greatest differences in the estimated relevance (>1.10) were found for issues on incontinence, masturbation, pain and fear, always rated higher by the interviewed HCPs (>1.0). Comparable results were found for issues for male sexual health (ejaculation) and issues on masculinity/femininity (,).
Table 4

Mean relevance for issues rated similar by patients and HCPs

IssuesMean relevance
PatientsHCPs
Frequency of sexual desire1.761.76
Level of desire1.701.79
Satisfaction with level of affection or intimacy2.242.31
The level of emotional intimacy2.102.13
Satisfaction communication partner2.352.43

HCPs, health care professionals.

Table 5

Mean relevance for issues rated different by patients and HCPs

IssuesMean relevance
PatientsHCPs
Incontinence0.872.39
Masturbation0.882.02
Frequency of pain during/after sexual activity1.392.54
Level of pain during/after sexual activity1.262.57
Fear that sex will be painful1.062.46
Fear of injury during intercourse0.872.08

HCPs, health care professionals.

HCPs, health care professionals. HCPs, health care professionals. Priority for inclusion was assessed in the same way for most of the 53 issues from the list. Only level of emotional intimacy and change in amount of affection expressed was much more higher prioritised by patients than by HCPs. Although many issues on body-related changes were less relevant for patients on average, they thought that these topics should be included in such a questionnaire of sexual health for cancer patients anyway (e.g., incontinence). Highest differences in the evaluated issues, identified for relevance and priority, were found for frequency of pain (during/after sexual activity), incontinence, fear that sex will be painful, and for communication about sexual issues with HCPs. While the interviewed HCPs found those issues more important to integrate in the sexual health questionnaire, patients found them less relevant.

Item development

On the basis of the results a provisional item list was established (“EORTC SHQ-Cxx”), supported by the translation coordinator of the EORTC Quality of Life Department. Issues fulfilling all four criteria on relevance and priority were automatically included. Issues within the categories of sexual desire, sexual arousal and pain were combined each. Issues implying norms, such as frequencies or content-related redundancy were not included. Negative wording or ambiguity was additional reasons for exclusion. The reduced list of 22 items with an additional question on reasons for not being sexually active was reviewed by two independent native English speakers before starting the translations process. At least three languages representing an English-speaking country, a country from Northern and Southern Europe were invited for preparation of pilot-testing, which is the next step in the EORTC procedure to develop a validated EORTC questionnaire.

Discussion

The results of the literature search were considered for the development of the issue list which was presented to patients and HCPs. Interview results were then analysed and item development process was done before continuing with pretesting. Studies on sexuality in oncology patients which were found in the literature search predominantly focused on issues of activity, experiences of sexual dysfunction, and satisfaction with sexual functioning. The literature review identified themes beyond these aspects and provided interesting results on current instruments used for measuring sexual health. No questionnaire currently exists that focuses on physical, psychological, and social aspects of sexuality for cancer survivors. Based on the available interview results most important issues to fill this gap were identified: satisfaction and the importance of having an active sexual life such as the level of confidence in getting an erection and keeping one for male patients. Different evaluations by HCPs and patients were found for most of the issues. Pain, incontinence, fear and communication about sexual issues with HCPs were issues which were highly relevant for HCPs but not for patients. Less research exists, in which possible reasons have been identified. Body image can change during different phases of cancer treatment. As shown in a review article by Cororve Gingeret et al. 2014 (22) patients are found to be most concerned about body image in the immediate postoperative period and soon after completing other forms of treatment (23). In a study with 225 Canadian cancer patients, 44% used the Internet to learn more about their condition and 14% wished their medical teams had provided them with links, but did not independently search for medically relevant information about their condition. While education level was correlated with web based information seeking, age was not (24). Why fear as an issue was less important for our interviewed patients than for professionals would be interesting to further investigate. Strength of the study is the fact that the development of the sexual health questionnaire is based on current literature, patient and HCP interviews from many different countries according to the EORTC guidelines (21). The literature review systematically examined sexual health issues in cancer beyond general ratings of sexual activity, symptoms, and sexual dysfunction. As other literature reviews (25-28) have described patients’ sexual activities, types of sexual dysfunction and generic levels of sexual satisfaction, this review uniquely took as its focus sexual health issues for all cancer patients and survivors. Including interviews of more than 100 patients with different cancer sites and many professionals from different disciplines also increases the quality of the development process. The provisional module will then be pre-tested in various languages to identify and solve potential problems with wording. For pilot-testing patients from many different countries and cultures are foreseen (phase 3) after the translation process was finished and ethical approval was done. Also the translations into several languages and the cross cultural distributions for developing the questions follow a standardized procedure (18). The questions are designed for male and female patients with different cancer sites during all stages of their disease. It is suggested that future studies broaden their focus to encompass sexual health related topics (body image, self-esteem, relationship functioning and communication) rated as important in cancer survivors which is not evident yet. But these issues should be addressed in clinical trials to get information on a possible impact for clinical practice. The instrument will be designed as a ‘stand-alone’ sexual health measure that can be used in clinical trials as well as in clinical studies. The results of trials which use the sexual health questionnaire adequately can improve sexual health care.
  22 in total

1.  Body image and sexual problems in young women with breast cancer.

Authors:  Pat Fobair; Susan L Stewart; Subo Chang; Carol D'Onofrio; Priscilla J Banks; Joan R Bloom
Journal:  Psychooncology       Date:  2006-07       Impact factor: 3.894

2.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning.

Authors:  P A Ganz; J H Rowland; K Desmond; B E Meyerowitz; G E Wyatt
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

Review 3.  Quality of life for women with gynecologic cancer.

Authors:  B L Andersen
Journal:  Curr Opin Obstet Gynecol       Date:  1995-02       Impact factor: 1.927

Review 4.  Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress.

Authors:  Andrew G Matthew; Adam Goldman; John Trachtenberg; John Robinson; Sheri Horsburgh; Kristen Currie; Paul Ritvo
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

5.  Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study.

Authors:  Patricia A Ganz; Katherine A Desmond; Beth Leedham; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

6.  Quality of life and sexual functioning in cervical cancer survivors.

Authors:  Michael Frumovitz; Charlotte C Sun; Leslie R Schover; Mark F Munsell; Anuja Jhingran; J Taylor Wharton; Patricia Eifel; Therese B Bevers; Charles F Levenback; David M Gershenson; Diane C Bodurka
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

7.  Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study.

Authors:  Elfriede R Greimel; Raimund Winter; Karin S Kapp; Josef Haas
Journal:  Psychooncology       Date:  2009-05       Impact factor: 3.894

8.  Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy.

Authors:  Jo A Broeckel; Christina L Thors; Paul B Jacobsen; Margaret Small; Charles E Cox
Journal:  Breast Cancer Res Treat       Date:  2002-10       Impact factor: 4.872

Review 9.  Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology.

Authors:  Diana D Jeffery; Janice P Tzeng; Francis J Keefe; Laura S Porter; Elizabeth A Hahn; Kathryn E Flynn; Bryce B Reeve; Kevin P Weinfurt
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

10.  The cancer patient's use and appreciation of the internet and other modern means of communication.

Authors:  J E Katz; D Roberge; G Coulombe
Journal:  Technol Cancer Res Treat       Date:  2013-08-31
View more
  3 in total

1.  Development, implementation and evaluation a palliative care program for colorectal cancer patients: a mixed methods protocol study.

Authors:  Masoud Bahrami; Masoumeh Masoumy; Alireza Sadeghi; Rohallah Mosavizadeh
Journal:  BMC Cancer       Date:  2022-04-22       Impact factor: 4.638

2.  Sexual Dysfunction in Carcinoma Cervix: Assessment in Post Treated Cases by LENTSOMA Scale.

Authors:  Abhishek Shankar; Jaineet Patil; Anil Luther; Kavita Mandrelle; Abhijit Chakraborty; Anusha Dubey; Deepak Saini; Ram Pukar Bharat; Deepak Abrol; Sachidanand Jee Bharti; Veronika Bentrad
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01

3.  Quality of Life in Papillary Thyroid Microcarcinoma Patients Undergoing Radiofrequency Ablation or Surgery: A Comparative Study.

Authors:  Yu Lan; Yukun Luo; Mingbo Zhang; Zhuang Jin; Jing Xiao; Lin Yan; Yaqiong Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.